Pharma & Healthcare
Global Multiple Myeloma Drugs Market Research Report 2024
- Jan 18, 24
- ID: 2982
- Pages: 92
- Figures: 196
- Views: 30
Multiple myeloma drugs fall into various drug classes, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), alkylating agents, corticosteriods, histone deactylase inhibitors (HDACs), bisphophonates, and monoclonal antibodies (MAbs).
The global Multiple Myeloma Drugs market was valued at US$ 874 million in 2023 and is anticipated to reach US$ 1271.1 million by 2030, witnessing a CAGR of 6.2% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Multiple Myeloma Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Multiple Myeloma Drugs.
Report Scope
The Multiple Myeloma Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Multiple Myeloma Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Multiple Myeloma Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
Johnson & Johnson
Celgene
Takeda Pharmaceutical
Novartis
Daiichi Sankyo
Merck
AB Science
Teva
PharmaMar
Segment by Type
Chemotherapy
Corticosteroids
Immunomodulators
Monoclonal Antibodies
Histone Deacetylase (HDAC) Inhibitors
Proteasome Inhibitors
Others
Segment by Application
Men
Women
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Multiple Myeloma Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Multiple Myeloma Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Multiple Myeloma Drugs market was valued at US$ 874 million in 2023 and is anticipated to reach US$ 1271.1 million by 2030, witnessing a CAGR of 6.2% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Multiple Myeloma Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Multiple Myeloma Drugs.
Report Scope
The Multiple Myeloma Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Multiple Myeloma Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Multiple Myeloma Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
Johnson & Johnson
Celgene
Takeda Pharmaceutical
Novartis
Daiichi Sankyo
Merck
AB Science
Teva
PharmaMar
Segment by Type
Chemotherapy
Corticosteroids
Immunomodulators
Monoclonal Antibodies
Histone Deacetylase (HDAC) Inhibitors
Proteasome Inhibitors
Others
Segment by Application
Men
Women
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Multiple Myeloma Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Multiple Myeloma Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Multiple Myeloma Drugs Market Overview
1.1 Product Overview and Scope of Multiple Myeloma Drugs
1.2 Multiple Myeloma Drugs Segment by Type
1.2.1 Global Multiple Myeloma Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Chemotherapy
1.2.3 Corticosteroids
1.2.4 Immunomodulators
1.2.5 Monoclonal Antibodies
1.2.6 Histone Deacetylase (HDAC) Inhibitors
1.2.7 Proteasome Inhibitors
1.2.8 Others
1.3 Multiple Myeloma Drugs Segment by Application
1.3.1 Global Multiple Myeloma Drugs Market Value by Application: (2024-2030)
1.3.2 Men
1.3.3 Women
1.4 Global Multiple Myeloma Drugs Market Size Estimates and Forecasts
1.4.1 Global Multiple Myeloma Drugs Revenue 2019-2030
1.4.2 Global Multiple Myeloma Drugs Sales 2019-2030
1.4.3 Global Multiple Myeloma Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Multiple Myeloma Drugs Market Competition by Manufacturers
2.1 Global Multiple Myeloma Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Multiple Myeloma Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Multiple Myeloma Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Multiple Myeloma Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Multiple Myeloma Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Multiple Myeloma Drugs, Product Type & Application
2.7 Multiple Myeloma Drugs Market Competitive Situation and Trends
2.7.1 Multiple Myeloma Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Multiple Myeloma Drugs Players Market Share by Revenue
2.7.3 Global Multiple Myeloma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Multiple Myeloma Drugs Retrospective Market Scenario by Region
3.1 Global Multiple Myeloma Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Multiple Myeloma Drugs Global Multiple Myeloma Drugs Sales by Region: 2019-2030
3.2.1 Global Multiple Myeloma Drugs Sales by Region: 2019-2024
3.2.2 Global Multiple Myeloma Drugs Sales by Region: 2025-2030
3.3 Global Multiple Myeloma Drugs Global Multiple Myeloma Drugs Revenue by Region: 2019-2030
3.3.1 Global Multiple Myeloma Drugs Revenue by Region: 2019-2024
3.3.2 Global Multiple Myeloma Drugs Revenue by Region: 2025-2030
3.4 North America Multiple Myeloma Drugs Market Facts & Figures by Country
3.4.1 North America Multiple Myeloma Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Multiple Myeloma Drugs Sales by Country (2019-2030)
3.4.3 North America Multiple Myeloma Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Multiple Myeloma Drugs Market Facts & Figures by Country
3.5.1 Europe Multiple Myeloma Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Multiple Myeloma Drugs Sales by Country (2019-2030)
3.5.3 Europe Multiple Myeloma Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Multiple Myeloma Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Multiple Myeloma Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Multiple Myeloma Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Multiple Myeloma Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Multiple Myeloma Drugs Market Facts & Figures by Country
3.7.1 Latin America Multiple Myeloma Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Multiple Myeloma Drugs Sales by Country (2019-2030)
3.7.3 Latin America Multiple Myeloma Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Multiple Myeloma Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Multiple Myeloma Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Multiple Myeloma Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Multiple Myeloma Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Multiple Myeloma Drugs Sales by Type (2019-2030)
4.1.1 Global Multiple Myeloma Drugs Sales by Type (2019-2024)
4.1.2 Global Multiple Myeloma Drugs Sales by Type (2025-2030)
4.1.3 Global Multiple Myeloma Drugs Sales Market Share by Type (2019-2030)
4.2 Global Multiple Myeloma Drugs Revenue by Type (2019-2030)
4.2.1 Global Multiple Myeloma Drugs Revenue by Type (2019-2024)
4.2.2 Global Multiple Myeloma Drugs Revenue by Type (2025-2030)
4.2.3 Global Multiple Myeloma Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Multiple Myeloma Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Multiple Myeloma Drugs Sales by Application (2019-2030)
5.1.1 Global Multiple Myeloma Drugs Sales by Application (2019-2024)
5.1.2 Global Multiple Myeloma Drugs Sales by Application (2025-2030)
5.1.3 Global Multiple Myeloma Drugs Sales Market Share by Application (2019-2030)
5.2 Global Multiple Myeloma Drugs Revenue by Application (2019-2030)
5.2.1 Global Multiple Myeloma Drugs Revenue by Application (2019-2024)
5.2.2 Global Multiple Myeloma Drugs Revenue by Application (2025-2030)
5.2.3 Global Multiple Myeloma Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Multiple Myeloma Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Corporation Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Amgen Multiple Myeloma Drugs Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Johnson & Johnson
6.2.1 Johnson & Johnson Corporation Information
6.2.2 Johnson & Johnson Description and Business Overview
6.2.3 Johnson & Johnson Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Johnson & Johnson Multiple Myeloma Drugs Product Portfolio
6.2.5 Johnson & Johnson Recent Developments/Updates
6.3 Celgene
6.3.1 Celgene Corporation Information
6.3.2 Celgene Description and Business Overview
6.3.3 Celgene Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Celgene Multiple Myeloma Drugs Product Portfolio
6.3.5 Celgene Recent Developments/Updates
6.4 Takeda Pharmaceutical
6.4.1 Takeda Pharmaceutical Corporation Information
6.4.2 Takeda Pharmaceutical Description and Business Overview
6.4.3 Takeda Pharmaceutical Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Takeda Pharmaceutical Multiple Myeloma Drugs Product Portfolio
6.4.5 Takeda Pharmaceutical Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Corporation Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Novartis Multiple Myeloma Drugs Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 Daiichi Sankyo
6.6.1 Daiichi Sankyo Corporation Information
6.6.2 Daiichi Sankyo Description and Business Overview
6.6.3 Daiichi Sankyo Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Daiichi Sankyo Multiple Myeloma Drugs Product Portfolio
6.6.5 Daiichi Sankyo Recent Developments/Updates
6.7 Merck
6.6.1 Merck Corporation Information
6.6.2 Merck Description and Business Overview
6.6.3 Merck Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Merck Multiple Myeloma Drugs Product Portfolio
6.7.5 Merck Recent Developments/Updates
6.8 AB Science
6.8.1 AB Science Corporation Information
6.8.2 AB Science Description and Business Overview
6.8.3 AB Science Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 AB Science Multiple Myeloma Drugs Product Portfolio
6.8.5 AB Science Recent Developments/Updates
6.9 Teva
6.9.1 Teva Corporation Information
6.9.2 Teva Description and Business Overview
6.9.3 Teva Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Teva Multiple Myeloma Drugs Product Portfolio
6.9.5 Teva Recent Developments/Updates
6.10 PharmaMar
6.10.1 PharmaMar Corporation Information
6.10.2 PharmaMar Description and Business Overview
6.10.3 PharmaMar Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 PharmaMar Multiple Myeloma Drugs Product Portfolio
6.10.5 PharmaMar Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Multiple Myeloma Drugs Industry Chain Analysis
7.2 Multiple Myeloma Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Multiple Myeloma Drugs Production Mode & Process
7.4 Multiple Myeloma Drugs Sales and Marketing
7.4.1 Multiple Myeloma Drugs Sales Channels
7.4.2 Multiple Myeloma Drugs Distributors
7.5 Multiple Myeloma Drugs Customers
8 Multiple Myeloma Drugs Market Dynamics
8.1 Multiple Myeloma Drugs Industry Trends
8.2 Multiple Myeloma Drugs Market Drivers
8.3 Multiple Myeloma Drugs Market Challenges
8.4 Multiple Myeloma Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Overview and Scope of Multiple Myeloma Drugs
1.2 Multiple Myeloma Drugs Segment by Type
1.2.1 Global Multiple Myeloma Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Chemotherapy
1.2.3 Corticosteroids
1.2.4 Immunomodulators
1.2.5 Monoclonal Antibodies
1.2.6 Histone Deacetylase (HDAC) Inhibitors
1.2.7 Proteasome Inhibitors
1.2.8 Others
1.3 Multiple Myeloma Drugs Segment by Application
1.3.1 Global Multiple Myeloma Drugs Market Value by Application: (2024-2030)
1.3.2 Men
1.3.3 Women
1.4 Global Multiple Myeloma Drugs Market Size Estimates and Forecasts
1.4.1 Global Multiple Myeloma Drugs Revenue 2019-2030
1.4.2 Global Multiple Myeloma Drugs Sales 2019-2030
1.4.3 Global Multiple Myeloma Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Multiple Myeloma Drugs Market Competition by Manufacturers
2.1 Global Multiple Myeloma Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Multiple Myeloma Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Multiple Myeloma Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Multiple Myeloma Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Multiple Myeloma Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Multiple Myeloma Drugs, Product Type & Application
2.7 Multiple Myeloma Drugs Market Competitive Situation and Trends
2.7.1 Multiple Myeloma Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Multiple Myeloma Drugs Players Market Share by Revenue
2.7.3 Global Multiple Myeloma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Multiple Myeloma Drugs Retrospective Market Scenario by Region
3.1 Global Multiple Myeloma Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Multiple Myeloma Drugs Global Multiple Myeloma Drugs Sales by Region: 2019-2030
3.2.1 Global Multiple Myeloma Drugs Sales by Region: 2019-2024
3.2.2 Global Multiple Myeloma Drugs Sales by Region: 2025-2030
3.3 Global Multiple Myeloma Drugs Global Multiple Myeloma Drugs Revenue by Region: 2019-2030
3.3.1 Global Multiple Myeloma Drugs Revenue by Region: 2019-2024
3.3.2 Global Multiple Myeloma Drugs Revenue by Region: 2025-2030
3.4 North America Multiple Myeloma Drugs Market Facts & Figures by Country
3.4.1 North America Multiple Myeloma Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Multiple Myeloma Drugs Sales by Country (2019-2030)
3.4.3 North America Multiple Myeloma Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Multiple Myeloma Drugs Market Facts & Figures by Country
3.5.1 Europe Multiple Myeloma Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Multiple Myeloma Drugs Sales by Country (2019-2030)
3.5.3 Europe Multiple Myeloma Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Multiple Myeloma Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Multiple Myeloma Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Multiple Myeloma Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Multiple Myeloma Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Multiple Myeloma Drugs Market Facts & Figures by Country
3.7.1 Latin America Multiple Myeloma Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Multiple Myeloma Drugs Sales by Country (2019-2030)
3.7.3 Latin America Multiple Myeloma Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Multiple Myeloma Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Multiple Myeloma Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Multiple Myeloma Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Multiple Myeloma Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Multiple Myeloma Drugs Sales by Type (2019-2030)
4.1.1 Global Multiple Myeloma Drugs Sales by Type (2019-2024)
4.1.2 Global Multiple Myeloma Drugs Sales by Type (2025-2030)
4.1.3 Global Multiple Myeloma Drugs Sales Market Share by Type (2019-2030)
4.2 Global Multiple Myeloma Drugs Revenue by Type (2019-2030)
4.2.1 Global Multiple Myeloma Drugs Revenue by Type (2019-2024)
4.2.2 Global Multiple Myeloma Drugs Revenue by Type (2025-2030)
4.2.3 Global Multiple Myeloma Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Multiple Myeloma Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Multiple Myeloma Drugs Sales by Application (2019-2030)
5.1.1 Global Multiple Myeloma Drugs Sales by Application (2019-2024)
5.1.2 Global Multiple Myeloma Drugs Sales by Application (2025-2030)
5.1.3 Global Multiple Myeloma Drugs Sales Market Share by Application (2019-2030)
5.2 Global Multiple Myeloma Drugs Revenue by Application (2019-2030)
5.2.1 Global Multiple Myeloma Drugs Revenue by Application (2019-2024)
5.2.2 Global Multiple Myeloma Drugs Revenue by Application (2025-2030)
5.2.3 Global Multiple Myeloma Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Multiple Myeloma Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Amgen
6.1.1 Amgen Corporation Information
6.1.2 Amgen Description and Business Overview
6.1.3 Amgen Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Amgen Multiple Myeloma Drugs Product Portfolio
6.1.5 Amgen Recent Developments/Updates
6.2 Johnson & Johnson
6.2.1 Johnson & Johnson Corporation Information
6.2.2 Johnson & Johnson Description and Business Overview
6.2.3 Johnson & Johnson Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Johnson & Johnson Multiple Myeloma Drugs Product Portfolio
6.2.5 Johnson & Johnson Recent Developments/Updates
6.3 Celgene
6.3.1 Celgene Corporation Information
6.3.2 Celgene Description and Business Overview
6.3.3 Celgene Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Celgene Multiple Myeloma Drugs Product Portfolio
6.3.5 Celgene Recent Developments/Updates
6.4 Takeda Pharmaceutical
6.4.1 Takeda Pharmaceutical Corporation Information
6.4.2 Takeda Pharmaceutical Description and Business Overview
6.4.3 Takeda Pharmaceutical Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Takeda Pharmaceutical Multiple Myeloma Drugs Product Portfolio
6.4.5 Takeda Pharmaceutical Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Corporation Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Novartis Multiple Myeloma Drugs Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 Daiichi Sankyo
6.6.1 Daiichi Sankyo Corporation Information
6.6.2 Daiichi Sankyo Description and Business Overview
6.6.3 Daiichi Sankyo Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Daiichi Sankyo Multiple Myeloma Drugs Product Portfolio
6.6.5 Daiichi Sankyo Recent Developments/Updates
6.7 Merck
6.6.1 Merck Corporation Information
6.6.2 Merck Description and Business Overview
6.6.3 Merck Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Merck Multiple Myeloma Drugs Product Portfolio
6.7.5 Merck Recent Developments/Updates
6.8 AB Science
6.8.1 AB Science Corporation Information
6.8.2 AB Science Description and Business Overview
6.8.3 AB Science Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 AB Science Multiple Myeloma Drugs Product Portfolio
6.8.5 AB Science Recent Developments/Updates
6.9 Teva
6.9.1 Teva Corporation Information
6.9.2 Teva Description and Business Overview
6.9.3 Teva Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Teva Multiple Myeloma Drugs Product Portfolio
6.9.5 Teva Recent Developments/Updates
6.10 PharmaMar
6.10.1 PharmaMar Corporation Information
6.10.2 PharmaMar Description and Business Overview
6.10.3 PharmaMar Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 PharmaMar Multiple Myeloma Drugs Product Portfolio
6.10.5 PharmaMar Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Multiple Myeloma Drugs Industry Chain Analysis
7.2 Multiple Myeloma Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Multiple Myeloma Drugs Production Mode & Process
7.4 Multiple Myeloma Drugs Sales and Marketing
7.4.1 Multiple Myeloma Drugs Sales Channels
7.4.2 Multiple Myeloma Drugs Distributors
7.5 Multiple Myeloma Drugs Customers
8 Multiple Myeloma Drugs Market Dynamics
8.1 Multiple Myeloma Drugs Industry Trends
8.2 Multiple Myeloma Drugs Market Drivers
8.3 Multiple Myeloma Drugs Market Challenges
8.4 Multiple Myeloma Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Multiple Myeloma Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Multiple Myeloma Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Multiple Myeloma Drugs Market Competitive Situation by Manufacturers in 2023
Table 4. Global Multiple Myeloma Drugs Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Multiple Myeloma Drugs Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Multiple Myeloma Drugs Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Multiple Myeloma Drugs Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Multiple Myeloma Drugs Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Multiple Myeloma Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Multiple Myeloma Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Multiple Myeloma Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Multiple Myeloma Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Multiple Myeloma Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multiple Myeloma Drugs as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Multiple Myeloma Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Multiple Myeloma Drugs Sales by Region (2019-2024) & (K Units)
Table 18. Global Multiple Myeloma Drugs Sales Market Share by Region (2019-2024)
Table 19. Global Multiple Myeloma Drugs Sales by Region (2025-2030) & (K Units)
Table 20. Global Multiple Myeloma Drugs Sales Market Share by Region (2025-2030)
Table 21. Global Multiple Myeloma Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Multiple Myeloma Drugs Revenue Market Share by Region (2019-2024)
Table 23. Global Multiple Myeloma Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Multiple Myeloma Drugs Revenue Market Share by Region (2025-2030)
Table 25. North America Multiple Myeloma Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Multiple Myeloma Drugs Sales by Country (2019-2024) & (K Units)
Table 27. North America Multiple Myeloma Drugs Sales by Country (2025-2030) & (K Units)
Table 28. North America Multiple Myeloma Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Multiple Myeloma Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Multiple Myeloma Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Multiple Myeloma Drugs Sales by Country (2019-2024) & (K Units)
Table 32. Europe Multiple Myeloma Drugs Sales by Country (2025-2030) & (K Units)
Table 33. Europe Multiple Myeloma Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Multiple Myeloma Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Multiple Myeloma Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Multiple Myeloma Drugs Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Multiple Myeloma Drugs Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Multiple Myeloma Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Multiple Myeloma Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Multiple Myeloma Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Multiple Myeloma Drugs Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Multiple Myeloma Drugs Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Multiple Myeloma Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Multiple Myeloma Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Multiple Myeloma Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Multiple Myeloma Drugs Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Multiple Myeloma Drugs Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Multiple Myeloma Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Multiple Myeloma Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Multiple Myeloma Drugs Sales (K Units) by Type (2019-2024)
Table 51. Global Multiple Myeloma Drugs Sales (K Units) by Type (2025-2030)
Table 52. Global Multiple Myeloma Drugs Sales Market Share by Type (2019-2024)
Table 53. Global Multiple Myeloma Drugs Sales Market Share by Type (2025-2030)
Table 54. Global Multiple Myeloma Drugs Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Multiple Myeloma Drugs Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Multiple Myeloma Drugs Revenue Market Share by Type (2019-2024)
Table 57. Global Multiple Myeloma Drugs Revenue Market Share by Type (2025-2030)
Table 58. Global Multiple Myeloma Drugs Price (USD/Unit) by Type (2019-2024)
Table 59. Global Multiple Myeloma Drugs Price (USD/Unit) by Type (2025-2030)
Table 60. Global Multiple Myeloma Drugs Sales (K Units) by Application (2019-2024)
Table 61. Global Multiple Myeloma Drugs Sales (K Units) by Application (2025-2030)
Table 62. Global Multiple Myeloma Drugs Sales Market Share by Application (2019-2024)
Table 63. Global Multiple Myeloma Drugs Sales Market Share by Application (2025-2030)
Table 64. Global Multiple Myeloma Drugs Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Multiple Myeloma Drugs Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Multiple Myeloma Drugs Revenue Market Share by Application (2019-2024)
Table 67. Global Multiple Myeloma Drugs Revenue Market Share by Application (2025-2030)
Table 68. Global Multiple Myeloma Drugs Price (USD/Unit) by Application (2019-2024)
Table 69. Global Multiple Myeloma Drugs Price (USD/Unit) by Application (2025-2030)
Table 70. Amgen Corporation Information
Table 71. Amgen Description and Business Overview
Table 72. Amgen Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 73. Amgen Multiple Myeloma Drugs Product
Table 74. Amgen Recent Developments/Updates
Table 75. Johnson & Johnson Corporation Information
Table 76. Johnson & Johnson Description and Business Overview
Table 77. Johnson & Johnson Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 78. Johnson & Johnson Multiple Myeloma Drugs Product
Table 79. Johnson & Johnson Recent Developments/Updates
Table 80. Celgene Corporation Information
Table 81. Celgene Description and Business Overview
Table 82. Celgene Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 83. Celgene Multiple Myeloma Drugs Product
Table 84. Celgene Recent Developments/Updates
Table 85. Takeda Pharmaceutical Corporation Information
Table 86. Takeda Pharmaceutical Description and Business Overview
Table 87. Takeda Pharmaceutical Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 88. Takeda Pharmaceutical Multiple Myeloma Drugs Product
Table 89. Takeda Pharmaceutical Recent Developments/Updates
Table 90. Novartis Corporation Information
Table 91. Novartis Description and Business Overview
Table 92. Novartis Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 93. Novartis Multiple Myeloma Drugs Product
Table 94. Novartis Recent Developments/Updates
Table 95. Daiichi Sankyo Corporation Information
Table 96. Daiichi Sankyo Description and Business Overview
Table 97. Daiichi Sankyo Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 98. Daiichi Sankyo Multiple Myeloma Drugs Product
Table 99. Daiichi Sankyo Recent Developments/Updates
Table 100. Merck Corporation Information
Table 101. Merck Description and Business Overview
Table 102. Merck Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 103. Merck Multiple Myeloma Drugs Product
Table 104. Merck Recent Developments/Updates
Table 105. AB Science Corporation Information
Table 106. AB Science Description and Business Overview
Table 107. AB Science Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 108. AB Science Multiple Myeloma Drugs Product
Table 109. AB Science Recent Developments/Updates
Table 110. Teva Corporation Information
Table 111. Teva Description and Business Overview
Table 112. Teva Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 113. Teva Multiple Myeloma Drugs Product
Table 114. Teva Recent Developments/Updates
Table 115. PharmaMar Corporation Information
Table 116. PharmaMar Description and Business Overview
Table 117. PharmaMar Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 118. PharmaMar Multiple Myeloma Drugs Product
Table 119. PharmaMar Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Multiple Myeloma Drugs Distributors List
Table 123. Multiple Myeloma Drugs Customers List
Table 124. Multiple Myeloma Drugs Market Trends
Table 125. Multiple Myeloma Drugs Market Drivers
Table 126. Multiple Myeloma Drugs Market Challenges
Table 127. Multiple Myeloma Drugs Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Multiple Myeloma Drugs
Figure 2. Global Multiple Myeloma Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Multiple Myeloma Drugs Market Share by Type in 2023 & 2030
Figure 4. Chemotherapy Product Picture
Figure 5. Corticosteroids Product Picture
Figure 6. Immunomodulators Product Picture
Figure 7. Monoclonal Antibodies Product Picture
Figure 8. Histone Deacetylase (HDAC) Inhibitors Product Picture
Figure 9. Proteasome Inhibitors Product Picture
Figure 10. Others Product Picture
Figure 11. Global Multiple Myeloma Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 12. Global Multiple Myeloma Drugs Market Share by Application in 2023 & 2030
Figure 13. Men
Figure 14. Women
Figure 15. Global Multiple Myeloma Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Multiple Myeloma Drugs Market Size (2019-2030) & (US$ Million)
Figure 17. Global Multiple Myeloma Drugs Sales (2019-2030) & (K Units)
Figure 18. Global Multiple Myeloma Drugs Average Price (USD/Unit) & (2019-2030)
Figure 19. Multiple Myeloma Drugs Report Years Considered
Figure 20. Multiple Myeloma Drugs Sales Share by Manufacturers in 2023
Figure 21. Global Multiple Myeloma Drugs Revenue Share by Manufacturers in 2023
Figure 22. The Global 5 and 10 Largest Multiple Myeloma Drugs Players: Market Share by Revenue in 2023
Figure 23. Multiple Myeloma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 24. Global Multiple Myeloma Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 25. North America Multiple Myeloma Drugs Sales Market Share by Country (2019-2030)
Figure 26. North America Multiple Myeloma Drugs Revenue Market Share by Country (2019-2030)
Figure 27. U.S. Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. Canada Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Europe Multiple Myeloma Drugs Sales Market Share by Country (2019-2030)
Figure 30. Europe Multiple Myeloma Drugs Revenue Market Share by Country (2019-2030)
Figure 31. Germany Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. France Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. U.K. Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Italy Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Russia Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Asia Pacific Multiple Myeloma Drugs Sales Market Share by Region (2019-2030)
Figure 37. Asia Pacific Multiple Myeloma Drugs Revenue Market Share by Region (2019-2030)
Figure 38. China Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Japan Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. South Korea Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. India Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Australia Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Taiwan Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Indonesia Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Thailand Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Malaysia Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Philippines Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Latin America Multiple Myeloma Drugs Sales Market Share by Country (2019-2030)
Figure 49. Latin America Multiple Myeloma Drugs Revenue Market Share by Country (2019-2030)
Figure 50. Mexico Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Brazil Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Argentina Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Middle East & Africa Multiple Myeloma Drugs Sales Market Share by Country (2019-2030)
Figure 54. Middle East & Africa Multiple Myeloma Drugs Revenue Market Share by Country (2019-2030)
Figure 55. Turkey Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 56. Saudi Arabia Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 57. UAE Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 58. Global Sales Market Share of Multiple Myeloma Drugs by Type (2019-2030)
Figure 59. Global Revenue Market Share of Multiple Myeloma Drugs by Type (2019-2030)
Figure 60. Global Multiple Myeloma Drugs Price (USD/Unit) by Type (2019-2030)
Figure 61. Global Sales Market Share of Multiple Myeloma Drugs by Application (2019-2030)
Figure 62. Global Revenue Market Share of Multiple Myeloma Drugs by Application (2019-2030)
Figure 63. Global Multiple Myeloma Drugs Price (USD/Unit) by Application (2019-2030)
Figure 64. Multiple Myeloma Drugs Value Chain
Figure 65. Multiple Myeloma Drugs Production Process
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Distributors Profiles
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Table 1. Global Multiple Myeloma Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Multiple Myeloma Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Multiple Myeloma Drugs Market Competitive Situation by Manufacturers in 2023
Table 4. Global Multiple Myeloma Drugs Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Multiple Myeloma Drugs Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Multiple Myeloma Drugs Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Multiple Myeloma Drugs Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Multiple Myeloma Drugs Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Multiple Myeloma Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Multiple Myeloma Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Multiple Myeloma Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Multiple Myeloma Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Multiple Myeloma Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multiple Myeloma Drugs as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Multiple Myeloma Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Multiple Myeloma Drugs Sales by Region (2019-2024) & (K Units)
Table 18. Global Multiple Myeloma Drugs Sales Market Share by Region (2019-2024)
Table 19. Global Multiple Myeloma Drugs Sales by Region (2025-2030) & (K Units)
Table 20. Global Multiple Myeloma Drugs Sales Market Share by Region (2025-2030)
Table 21. Global Multiple Myeloma Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Multiple Myeloma Drugs Revenue Market Share by Region (2019-2024)
Table 23. Global Multiple Myeloma Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Multiple Myeloma Drugs Revenue Market Share by Region (2025-2030)
Table 25. North America Multiple Myeloma Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Multiple Myeloma Drugs Sales by Country (2019-2024) & (K Units)
Table 27. North America Multiple Myeloma Drugs Sales by Country (2025-2030) & (K Units)
Table 28. North America Multiple Myeloma Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Multiple Myeloma Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Multiple Myeloma Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Multiple Myeloma Drugs Sales by Country (2019-2024) & (K Units)
Table 32. Europe Multiple Myeloma Drugs Sales by Country (2025-2030) & (K Units)
Table 33. Europe Multiple Myeloma Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Multiple Myeloma Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Multiple Myeloma Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Multiple Myeloma Drugs Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Multiple Myeloma Drugs Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Multiple Myeloma Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Multiple Myeloma Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Multiple Myeloma Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Multiple Myeloma Drugs Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Multiple Myeloma Drugs Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Multiple Myeloma Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Multiple Myeloma Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Multiple Myeloma Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Multiple Myeloma Drugs Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Multiple Myeloma Drugs Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Multiple Myeloma Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Multiple Myeloma Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Multiple Myeloma Drugs Sales (K Units) by Type (2019-2024)
Table 51. Global Multiple Myeloma Drugs Sales (K Units) by Type (2025-2030)
Table 52. Global Multiple Myeloma Drugs Sales Market Share by Type (2019-2024)
Table 53. Global Multiple Myeloma Drugs Sales Market Share by Type (2025-2030)
Table 54. Global Multiple Myeloma Drugs Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Multiple Myeloma Drugs Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Multiple Myeloma Drugs Revenue Market Share by Type (2019-2024)
Table 57. Global Multiple Myeloma Drugs Revenue Market Share by Type (2025-2030)
Table 58. Global Multiple Myeloma Drugs Price (USD/Unit) by Type (2019-2024)
Table 59. Global Multiple Myeloma Drugs Price (USD/Unit) by Type (2025-2030)
Table 60. Global Multiple Myeloma Drugs Sales (K Units) by Application (2019-2024)
Table 61. Global Multiple Myeloma Drugs Sales (K Units) by Application (2025-2030)
Table 62. Global Multiple Myeloma Drugs Sales Market Share by Application (2019-2024)
Table 63. Global Multiple Myeloma Drugs Sales Market Share by Application (2025-2030)
Table 64. Global Multiple Myeloma Drugs Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Multiple Myeloma Drugs Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Multiple Myeloma Drugs Revenue Market Share by Application (2019-2024)
Table 67. Global Multiple Myeloma Drugs Revenue Market Share by Application (2025-2030)
Table 68. Global Multiple Myeloma Drugs Price (USD/Unit) by Application (2019-2024)
Table 69. Global Multiple Myeloma Drugs Price (USD/Unit) by Application (2025-2030)
Table 70. Amgen Corporation Information
Table 71. Amgen Description and Business Overview
Table 72. Amgen Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 73. Amgen Multiple Myeloma Drugs Product
Table 74. Amgen Recent Developments/Updates
Table 75. Johnson & Johnson Corporation Information
Table 76. Johnson & Johnson Description and Business Overview
Table 77. Johnson & Johnson Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 78. Johnson & Johnson Multiple Myeloma Drugs Product
Table 79. Johnson & Johnson Recent Developments/Updates
Table 80. Celgene Corporation Information
Table 81. Celgene Description and Business Overview
Table 82. Celgene Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 83. Celgene Multiple Myeloma Drugs Product
Table 84. Celgene Recent Developments/Updates
Table 85. Takeda Pharmaceutical Corporation Information
Table 86. Takeda Pharmaceutical Description and Business Overview
Table 87. Takeda Pharmaceutical Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 88. Takeda Pharmaceutical Multiple Myeloma Drugs Product
Table 89. Takeda Pharmaceutical Recent Developments/Updates
Table 90. Novartis Corporation Information
Table 91. Novartis Description and Business Overview
Table 92. Novartis Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 93. Novartis Multiple Myeloma Drugs Product
Table 94. Novartis Recent Developments/Updates
Table 95. Daiichi Sankyo Corporation Information
Table 96. Daiichi Sankyo Description and Business Overview
Table 97. Daiichi Sankyo Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 98. Daiichi Sankyo Multiple Myeloma Drugs Product
Table 99. Daiichi Sankyo Recent Developments/Updates
Table 100. Merck Corporation Information
Table 101. Merck Description and Business Overview
Table 102. Merck Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 103. Merck Multiple Myeloma Drugs Product
Table 104. Merck Recent Developments/Updates
Table 105. AB Science Corporation Information
Table 106. AB Science Description and Business Overview
Table 107. AB Science Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 108. AB Science Multiple Myeloma Drugs Product
Table 109. AB Science Recent Developments/Updates
Table 110. Teva Corporation Information
Table 111. Teva Description and Business Overview
Table 112. Teva Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 113. Teva Multiple Myeloma Drugs Product
Table 114. Teva Recent Developments/Updates
Table 115. PharmaMar Corporation Information
Table 116. PharmaMar Description and Business Overview
Table 117. PharmaMar Multiple Myeloma Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 118. PharmaMar Multiple Myeloma Drugs Product
Table 119. PharmaMar Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Multiple Myeloma Drugs Distributors List
Table 123. Multiple Myeloma Drugs Customers List
Table 124. Multiple Myeloma Drugs Market Trends
Table 125. Multiple Myeloma Drugs Market Drivers
Table 126. Multiple Myeloma Drugs Market Challenges
Table 127. Multiple Myeloma Drugs Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Multiple Myeloma Drugs
Figure 2. Global Multiple Myeloma Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Multiple Myeloma Drugs Market Share by Type in 2023 & 2030
Figure 4. Chemotherapy Product Picture
Figure 5. Corticosteroids Product Picture
Figure 6. Immunomodulators Product Picture
Figure 7. Monoclonal Antibodies Product Picture
Figure 8. Histone Deacetylase (HDAC) Inhibitors Product Picture
Figure 9. Proteasome Inhibitors Product Picture
Figure 10. Others Product Picture
Figure 11. Global Multiple Myeloma Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 12. Global Multiple Myeloma Drugs Market Share by Application in 2023 & 2030
Figure 13. Men
Figure 14. Women
Figure 15. Global Multiple Myeloma Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Multiple Myeloma Drugs Market Size (2019-2030) & (US$ Million)
Figure 17. Global Multiple Myeloma Drugs Sales (2019-2030) & (K Units)
Figure 18. Global Multiple Myeloma Drugs Average Price (USD/Unit) & (2019-2030)
Figure 19. Multiple Myeloma Drugs Report Years Considered
Figure 20. Multiple Myeloma Drugs Sales Share by Manufacturers in 2023
Figure 21. Global Multiple Myeloma Drugs Revenue Share by Manufacturers in 2023
Figure 22. The Global 5 and 10 Largest Multiple Myeloma Drugs Players: Market Share by Revenue in 2023
Figure 23. Multiple Myeloma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 24. Global Multiple Myeloma Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 25. North America Multiple Myeloma Drugs Sales Market Share by Country (2019-2030)
Figure 26. North America Multiple Myeloma Drugs Revenue Market Share by Country (2019-2030)
Figure 27. U.S. Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. Canada Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Europe Multiple Myeloma Drugs Sales Market Share by Country (2019-2030)
Figure 30. Europe Multiple Myeloma Drugs Revenue Market Share by Country (2019-2030)
Figure 31. Germany Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. France Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. U.K. Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Italy Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Russia Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Asia Pacific Multiple Myeloma Drugs Sales Market Share by Region (2019-2030)
Figure 37. Asia Pacific Multiple Myeloma Drugs Revenue Market Share by Region (2019-2030)
Figure 38. China Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Japan Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. South Korea Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. India Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Australia Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Taiwan Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Indonesia Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Thailand Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Malaysia Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Philippines Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Latin America Multiple Myeloma Drugs Sales Market Share by Country (2019-2030)
Figure 49. Latin America Multiple Myeloma Drugs Revenue Market Share by Country (2019-2030)
Figure 50. Mexico Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Brazil Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Argentina Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Middle East & Africa Multiple Myeloma Drugs Sales Market Share by Country (2019-2030)
Figure 54. Middle East & Africa Multiple Myeloma Drugs Revenue Market Share by Country (2019-2030)
Figure 55. Turkey Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 56. Saudi Arabia Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 57. UAE Multiple Myeloma Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 58. Global Sales Market Share of Multiple Myeloma Drugs by Type (2019-2030)
Figure 59. Global Revenue Market Share of Multiple Myeloma Drugs by Type (2019-2030)
Figure 60. Global Multiple Myeloma Drugs Price (USD/Unit) by Type (2019-2030)
Figure 61. Global Sales Market Share of Multiple Myeloma Drugs by Application (2019-2030)
Figure 62. Global Revenue Market Share of Multiple Myeloma Drugs by Application (2019-2030)
Figure 63. Global Multiple Myeloma Drugs Price (USD/Unit) by Application (2019-2030)
Figure 64. Multiple Myeloma Drugs Value Chain
Figure 65. Multiple Myeloma Drugs Production Process
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Distributors Profiles
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Paint Leveling Agent Market Insights, Forecast to 2030
Dec 22, 24
Global Paint Adhesion Promoters Market Insights, Forecast to 2030
Dec 22, 24
Global Paint Rheological Additives Market Insights, Forecast to 2030
Dec 22, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232